Open-Label Extension (OLE) Safety and Efficacy Study of Velneperit (S-2367) Following the Year-Long Controlled Clinical Trials of S-2367 in Obese Males and Females.
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2011
At a glance
- Drugs Velneperit (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shionogi USA
- 26 Mar 2010 Actual patient number (766) added as reported by ClinicalTrials.gov.
- 26 Mar 2010 Actual end date (March 2010) added as reported by ClinicalTrials.gov.
- 26 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.